Skip to content

Study · Systematic review · n = 4,754 · 2019

4 results

The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.

Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y

African health sciences1 Sept 2019Cited by 27 (Europe PMC)

PMID32127832 (opens in a new tab)PMCIDPMC7040262 (opens in a new tab)DOI10.4314/ahs.v19i3.35 (opens in a new tab)PepBankPUB-32127832
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundLiraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted.ObjectivesThe aim of this study is to carry out a meta-analysis to assess the efficacy and safety of liraglutide in the obese, non-diabetic individuals.MethodsA literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals. The search included the following databases: EMBASE, MEDLINE and the Cochrane Controlled Trials Register.ResultsWe included five publications involving a total of 4,754 patients that compared liraglutide with placebo and found that liraglutide to be an effective and safe treatment for weight loss in individuals without diabetes. Primary efficacy end points: mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001); lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001) and key secondary efficacy end points: SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001). Safety assessments included the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009), and nausea indicated that liraglutide was well tolerated.ConclusionThis systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In obese adults without diabetes, liraglutide produced greater mean weight loss than placebo in a meta-analysis of five publications.

    In plain wordsIn obese adults without diabetes, liraglutide led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight loss
    Study

    n = 4,754

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight loss
    −5.52 MD
    liraglutide vs placebo

    Source sentences

    Summary
    mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001)
    1 context sentence
    Summary · context
    A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals.
  2. 02HumanSystematic reviewEfficacy outcome

    In obese adults without diabetes, more people lost more than 5% of body weight with liraglutide than with placebo (OR 5.46).

    In plain wordsIn obese adults without diabetes, more people lost over 5% of their body weight with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseLoss of more than 5% of body weight
    Study

    n = 4,754

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    5.46 OR
    loss >5% body weight

    Source sentences

    Summary
    lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001)
    1 context sentence
    Summary · context
    A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals.
  3. 03HumanSystematic reviewEfficacy outcome

    In obese adults without diabetes, systolic blood pressure decreased more with liraglutide than with placebo.

    In plain wordsIn obese adults without diabetes, liraglutide lowered systolic blood pressure more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 4,754

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference in SBP
    −2.56 MD
    liraglutide vs placebo

    Source sentences

    Summary
    SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001).
    1 context sentence
    Summary · context
    A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals.
  4. 04HumanSystematic reviewSafety outcome

    In obese adults without diabetes, the odds of withdrawal due to adverse events with liraglutide versus placebo were OR 2.85 (95% CI 0.84 to 9.62).

    In plain wordsIn obese adults without diabetes, the abstract reports withdrawal due to side effects with liraglutide versus placebo, and calls liraglutide well tolerated.

    Peptide
    Liraglutide
    Outcome
    MixedWithdrawal due to adverse events
    Study

    n = 4,754

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    2.85 OR
    withdrawal due to AE

    Source sentences

    Summary
    the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009)
    1 context sentence
    Summary · context
    A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.